MOREPEN LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of MOREPEN LABORATORIES have increased by 19.25% YoY .
The Earnings Per Share (EPS) of MOREPEN LABORATORIES has increased by 147.37 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
MOREPEN LABORATORIES Last 5 Annual Financial Results
[BOM: 500288|NSE : MOREPENLAB]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹1,690 Cr | ₹1,418 Cr | ₹1,547 Cr | ₹1,188 Cr | ₹853 Cr |
| Expenses | ₹1,532 Cr | ₹1,338 Cr | ₹1,410 Cr | ₹1,070 Cr | ₹785 Cr |
| Operating Profit (Excl OI) | ₹159 Cr | ₹80 Cr | ₹137 Cr | ₹119 Cr | ₹69 Cr |
| Other Income | ₹14 Cr | ₹6.13 Cr | ₹20 Cr | ₹12 Cr | ₹9.48 Cr |
| Interest | ₹3.71 Cr | ₹1.98 Cr | ₹2.43 Cr | ₹1.79 Cr | ₹1.99 Cr |
| Depreciation | ₹33 Cr | ₹28 Cr | ₹28 Cr | ₹30 Cr | ₹37 Cr |
| Profit Before Tax | ₹135 Cr | ₹56 Cr | ₹127 Cr | ₹99 Cr | ₹39 Cr |
| Profit After Tax | ₹97 Cr | ₹39 Cr | ₹102 Cr | ₹97 Cr | ₹34 Cr |
| Consolidated Net Profit | ₹96 Cr | ₹39 Cr | ₹102 Cr | ₹97 Cr | ₹34 Cr |
| Earnings Per Share (Rs) | ₹1.88 | ₹0.76 | ₹2.13 | ₹2.16 | ₹0.75 |
| PAT Margin (%) | 5.72 | 2.73 | 6.57 | 8.17 | 3.94 |
| ROE(%) | 12.08 | 5.93 | 21.79 | 29.20 | 12.50 |
| ROCE(%) | 16.82 | 8.40 | 24.86 | 27.13 | 12.05 |
| Total Debt/Equity(x) | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 |
Key Financials |
||
| Market Cap | : | ₹ 4,145.6 Cr |
| Revenue (TTM) | : | ₹ 1,760.6 Cr |
| Net Profit(TTM) | : | ₹ 131.7 Cr |
| EPS (TTM) | : | ₹ 2.4 |
| P/E (TTM) | : | 31.5 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| MOREPEN LABORATORIES | -3.9% | -0.6% | 57% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.9% | 6.4% | 48.1% |
| CIPLA | 2.3% | 1% | 20.6% |
| DR REDDYS LABORATORIES | 3.5% | 15.7% | 20.3% |
| ZYDUS LIFESCIENCES | -0.1% | 2.3% | 41.1% |
| DIVIS LABORATORIES | 0.5% | -2.1% | 59.2% |
| MANKIND PHARMA | 2.5% | 12.4% | 50.8% |
| TORRENT PHARMACEUTICALS | -0.8% | 5.7% | 54.3% |
| LUPIN | 3.8% | 11.1% | 72.6% |
MOREPEN LABORATORIES Revenues
[BOM: 500288|NSE : MOREPENLAB]
| Y-o-Y | 19.25 % |
| 5 Yr CAGR | 18.65 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,690 Cr | 19.25 | |
| Mar2023 | ₹1,418 Cr | -8.36 | |
| Mar2022 | ₹1,547 Cr | 30.20 | |
| Mar2021 | ₹1,188 Cr | 39.27 | |
| Mar2020 | ₹853 Cr | - | |
MOREPEN LABORATORIES Operating Profit
[BOM: 500288|NSE : MOREPENLAB]
| Y-o-Y | 99.45 % |
| 5 Yr CAGR | 23.35 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹159 Cr | 99.45 | |
| Mar2023 | ₹80 Cr | -41.81 | |
| Mar2022 | ₹137 Cr | 15.32 | |
| Mar2021 | ₹119 Cr | 72.98 | |
| Mar2020 | ₹69 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 67.20 % |
| 5 Yr CAGR | 3.96 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 9.38% | 67.20 | |
| Mar2023 | 5.61% | -36.54 | |
| Mar2022 | 8.84% | -11.42 | |
| Mar2021 | 9.98% | 24.28 | |
| Mar2020 | 8.03% | - | |
MOREPEN LABORATORIES Profit After Tax
[BOM: 500288|NSE : MOREPENLAB]
| Y-o-Y | 148.64 % |
| 5 Yr CAGR | 30.09 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹96 Cr | 148.64 | |
| Mar2023 | ₹39 Cr | -61.97 | |
| Mar2022 | ₹102 Cr | 4.73 | |
| Mar2021 | ₹97 Cr | 189.13 | |
| Mar2020 | ₹34 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 109.52 % |
| 5 Yr CAGR | 9.77 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 5.72 % | 109.52 | |
| Mar2023 | 2.73 % | -58.45 | |
| Mar2022 | 6.57 % | -19.58 | |
| Mar2021 | 8.17 % | 107.36 | |
| Mar2020 | 3.94 % | - | |
MOREPEN LABORATORIES Earnings Per Share (EPS)
[BOM: 500288|NSE : MOREPENLAB]
| Y-o-Y | 147.37 % |
| 5 Yr CAGR | 25.83 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹1.88 | 147.37 | |
| Mar2023 | ₹0.76 | -64.32 | |
| Mar2022 | ₹2.13 | -1.39 | |
| Mar2021 | ₹2.16 | 188.00 | |
| Mar2020 | ₹0.75 | - | |
MOREPEN LABORATORIES Return on Capital Employed (ROCE)
[BOM: 500288|NSE : MOREPENLAB]
| Y-o-Y | 100.24 % |
| 5 Yr CAGR | 8.70 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 16.82% | 100.24 | |
| Mar2023 | 8.4% | -66.21 | |
| Mar2022 | 24.86% | -8.37 | |
| Mar2021 | 27.13% | 125.15 | |
| Mar2020 | 12.05% | - | |
MOREPEN LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹75.7 |
| Current MarketCap | : | ₹ 4,145.6 Cr |
| Updated EOD on | : | Dec 30,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MOREPEN LABORATORIES | -3.9% |
-0.6% |
57% |
| SENSEX | 0.3% |
-2.5% |
10% |
MOREPEN LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE HEALTHCARE | 2.4% | 5% | 46.9% |
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
| S&P BSE SMALL CAP | -0.7% | 0.4% | 30.5% |
| S&P BSE MIDSMALLCAP | -2.3% | 1.6% | 31.3% |
No NSE index found
You may also like the below Video Courses
FAQ about MOREPEN LABORATORIES Financials
How the annual revenues of MOREPEN LABORATORIES have changed ?
The Revenues of MOREPEN LABORATORIES have increased by 19.25% YoY .
How the Earnings per Share (EPS) of MOREPEN LABORATORIES have changed?
The Earnings Per Share (EPS) of MOREPEN LABORATORIES has increased by 147.37 % YoY .
Check out Intrinsic Value of Peers of MOREPEN LABORATORIES
Compare Stock Analytics of Peers of MOREPEN LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
